CA2676003C - Compositions of stable tiacumicins - Google Patents

Compositions of stable tiacumicins Download PDF

Info

Publication number
CA2676003C
CA2676003C CA2676003A CA2676003A CA2676003C CA 2676003 C CA2676003 C CA 2676003C CA 2676003 A CA2676003 A CA 2676003A CA 2676003 A CA2676003 A CA 2676003A CA 2676003 C CA2676003 C CA 2676003C
Authority
CA
Canada
Prior art keywords
composition
tiacumicins
pharmaceutical composition
solid dosage
antioxidants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2676003A
Other languages
English (en)
French (fr)
Other versions
CA2676003A1 (en
Inventor
Suketu Sanghvi
Mark Roach
Joseph F. Zhou
Ping He
Michael Mittleberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals LLC filed Critical Optimer Pharmaceuticals LLC
Publication of CA2676003A1 publication Critical patent/CA2676003A1/en
Application granted granted Critical
Publication of CA2676003C publication Critical patent/CA2676003C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2676003A 2007-01-19 2008-01-17 Compositions of stable tiacumicins Active CA2676003C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88113707P 2007-01-19 2007-01-19
US60/881,137 2007-01-19
PCT/US2008/000591 WO2008091518A1 (en) 2007-01-19 2008-01-17 Compositions of stable tiacumicins

Publications (2)

Publication Number Publication Date
CA2676003A1 CA2676003A1 (en) 2008-07-31
CA2676003C true CA2676003C (en) 2012-04-10

Family

ID=39641896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2676003A Active CA2676003C (en) 2007-01-19 2008-01-17 Compositions of stable tiacumicins

Country Status (22)

Country Link
US (2) US20080176927A1 (enExample)
EP (1) EP2121716B1 (enExample)
JP (2) JP5635266B2 (enExample)
KR (1) KR101491729B1 (enExample)
CN (2) CN105169396A (enExample)
BR (1) BRPI0806713A8 (enExample)
CA (1) CA2676003C (enExample)
CY (1) CY1117237T1 (enExample)
DK (1) DK2121716T3 (enExample)
ES (1) ES2560669T3 (enExample)
HR (1) HRP20151438T1 (enExample)
HU (1) HUE028671T2 (enExample)
IL (1) IL199941A (enExample)
MX (1) MX2009007784A (enExample)
NZ (1) NZ578493A (enExample)
PL (1) PL2121716T3 (enExample)
PT (1) PT2121716E (enExample)
RU (1) RU2484829C2 (enExample)
SI (1) SI2121716T1 (enExample)
TW (1) TWI474820B (enExample)
WO (1) WO2008091518A1 (enExample)
ZA (1) ZA200905134B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586551B2 (en) 2005-01-31 2013-11-19 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
BR112012029259A8 (pt) * 2010-05-18 2021-03-23 Optimer Pharmaceuticals Inc tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos
WO2011146624A2 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Methods of treating recurring bacterial infection
CN105287473A (zh) * 2010-06-02 2016-02-03 扩散药品有限公司 包含双极性反式类胡萝卜素的组合物及其应用
MX2013009033A (es) * 2011-02-04 2013-09-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones bacterianas.
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
WO2015169451A1 (en) * 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN112353774B (zh) * 2020-11-17 2022-08-23 浙江汇能生物股份有限公司 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192094A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 造粒組成物
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
WO2006085838A1 (en) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7507564B2 (en) * 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof

Also Published As

Publication number Publication date
NZ578493A (en) 2012-02-24
JP2014205701A (ja) 2014-10-30
US20130065844A1 (en) 2013-03-14
ES2560669T3 (es) 2016-02-22
AU2008209623A2 (en) 2010-01-28
DK2121716T3 (en) 2016-03-14
CN102015747A (zh) 2011-04-13
CA2676003A1 (en) 2008-07-31
PL2121716T3 (pl) 2016-04-29
PT2121716E (pt) 2016-03-03
TW200938187A (en) 2009-09-16
CN105169396A (zh) 2015-12-23
HRP20151438T1 (hr) 2016-01-29
US20080176927A1 (en) 2008-07-24
JP5635266B2 (ja) 2014-12-03
JP2010516677A (ja) 2010-05-20
BRPI0806713A2 (pt) 2011-09-13
SI2121716T1 (sl) 2016-03-31
KR101491729B1 (ko) 2015-02-09
KR20090107061A (ko) 2009-10-12
RU2484829C2 (ru) 2013-06-20
EP2121716A1 (en) 2009-11-25
EP2121716A4 (en) 2013-06-12
RU2009128612A (ru) 2011-02-27
AU2008209623A1 (en) 2008-07-31
EP2121716B1 (en) 2015-12-09
ZA200905134B (en) 2013-08-28
TWI474820B (zh) 2015-03-01
IL199941A0 (en) 2010-04-15
MX2009007784A (es) 2010-02-11
CY1117237T1 (el) 2017-04-05
WO2008091518A1 (en) 2008-07-31
JP5995331B2 (ja) 2016-09-21
IL199941A (en) 2016-02-29
BRPI0806713A8 (pt) 2017-04-18
HUE028671T2 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
EP2121716B1 (en) Compositions of stable tiacumicins
KR20210016436A (ko) 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
KR20120008017A (ko) 경구 투여를 위한 리나클로타이드-함유 제형
EP2029112A2 (en) Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
CN108348475A (zh) 处于液体剂型的多层药学活性化合物释放微粒
KR20200097564A (ko) 덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN114569579A (zh) 肠溶微丸、其制备方法和包含它的制剂
US9555003B2 (en) Oral solid formulation of compound anti-tubercular drug and preparation method thereof
AU2008209623B2 (en) Compositions of stable tiacumicins
KR101794573B1 (ko) 콜린알포세레이트를 포함하는 속방출형 고형제제 및 이의 제조방법
AU2013254941A1 (en) Compositions of stable tiacumicins
KR20150045446A (ko) 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
US20110020439A1 (en) Delayed release compositions of duloxetine
HK1156322A (en) Compositions of stable tiacumicins
CA2593825A1 (en) Solid dispersion comprising tacrolimus and enteric-coated macromolecule
HK1189504A (en) Oral solid preparation of compound antituberculosis drug and preparation method thereof
HK1189504B (en) Oral solid preparation of compound antituberculosis drug and preparation method thereof
HK1210053B (en) Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209